SG Americas Securities LLC Boosts Holdings in Arvinas, Inc. (NASDAQ:ARVN)

SG Americas Securities LLC grew its position in shares of Arvinas, Inc. (NASDAQ:ARVN) by 228.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,424 shares of the company’s stock after buying an additional 22,564 shares during the quarter. SG Americas Securities LLC’s holdings in Arvinas were worth $622,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. nVerses Capital LLC purchased a new position in Arvinas during the third quarter worth about $39,000. Mirae Asset Global Investments Co. Ltd. increased its position in Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after purchasing an additional 440 shares during the period. Quantbot Technologies LP raised its stake in shares of Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after buying an additional 2,601 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Arvinas by 37.0% in the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock valued at $164,000 after buying an additional 1,798 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Arvinas by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,203 shares of the company’s stock valued at $325,000 after buying an additional 5,163 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Stephens started coverage on Arvinas in a research report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective for the company. Guggenheim reiterated a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. BTIG Research assumed coverage on shares of Arvinas in a report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. Finally, Oppenheimer lowered their price target on Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $63.50.

Arvinas Trading Up 1.9 %

Arvinas stock opened at $17.89 on Friday. The stock has a 50-day moving average price of $20.47 and a 200 day moving average price of $24.09. Arvinas, Inc. has a 52 week low of $17.08 and a 52 week high of $53.08. The stock has a market cap of $1.23 billion, a PE ratio of -3.83 and a beta of 1.87.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.20. The firm had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. Arvinas’s revenue for the quarter was up 196.0% on a year-over-year basis. During the same period in the prior year, the business earned ($1.18) earnings per share. On average, equities analysts predict that Arvinas, Inc. will post -3.22 EPS for the current year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.